{
    "medicine_id": "c4000f3d3131291ab070c45fa794232c46efbb46",
    "platform_id": "DB04887",
    "metadata": {
        "name": "Galvus 50 mg Tablet",
        "composition": "50 mg Brecanavir",
        "clinical_particulars": {
            "therapeutic_indications": "For the treatment of HIV 1 infection in combination with other antiretroviral agents",
            "contraindications": {
                "disease": "NA",
                "pregnancy": "NA",
                "machine_ops": "NA",
                "pharmacodynamics": "Brecanavir is an orally active aspartic protease inhibitor PI under investigation by Vertex and GlaxoSmithKline for the treatment of HIV Test tube data suggest that it has activity against virus with resistance to the currently available protease inhibitors and that it is more powerful against wild type HIV that existing protease inhibitors being active at concentrations much lower than most existing protease inhibitors Unlike some other protease inhibitors brecanavir does not have a significant interaction with the nucleotide reverse transcriptase inhibitor NtRTI tenofovir Viread In December of 2006 GlaxoSmithKline announced their decision to discontinue the development of brecanavir for the treatment of HIV The decision was based on issues regarding the formulation of the drug",
                "excipients": "NA",
                "incompatibilities": []
            }
        },
        "revision_date": "2023-05-14"
    }
}